MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.49
+0.19
+0.85%
After Hours: 22.49 0 0.00% 16:00 07/06 EDT
OPEN
22.60
PREV CLOSE
22.30
HIGH
23.28
LOW
22.35
VOLUME
759.09K
TURNOVER
--
52 WEEK HIGH
24.32
52 WEEK LOW
9.18
MARKET CAP
1.26B
P/E (TTM)
-9.9942
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NTLA stock price target is 28.65 with a high estimate of 57.50 and a low estimate of 16.00.

EPS

NTLA News

More
Intellia Therapeutics, Inc. (NTLA): Hedge Funds Taking Some Chips Off The Table
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 1d ago
Better Buy: Editas Medicine vs. Intellia
Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?
Motley Fool · 4d ago
Strategic Allocation To Innovation: A Comparison To Emerging Markets
Seeking Alpha - Article · 06/13 16:22
Edited Transcript of NTLA earnings conference call or presentation 7-May-20 12:00pm GMT
Q1 2020 Intellia Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 06/11 03:48
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 05, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
GlobeNewswire · 06/05 20:01
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%
Zacks · 06/05 05:37
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
Zacks · 06/03 14:56

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About NTLA

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.